Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1181181 in Healthy Males
NCT02106247Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 1181181 in Alzheimer's disease (AD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: %-change from baseline of Aß1-40 in cerebrospinal fluid. Started Apr 2014; status: completed.
02
Drugs
BI 1181181
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02106247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106247.